[Treatment of rheumatoid arthritis with levamisole. Preliminary study of clinical and immunological results]. 1977

M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux

From September 1975 to September 1976, eleven patients suffering from rheumatoid arthritis in whom gold salts were either inactive or contraindicated were treated with levamisole. Treatment was interrupted in one case because of an allergic rash and in one as a precaution. There was an improvement in six, taking the form of a decrease in clinical symptoms and signs and a slowing of sedimentation rate. Certain immunitary changes were seen, in the sense of a reinforcement of humoural and cellular immunity. Fear of sudden agranulocytosis should lead to caution in further clinical trials.

UI MeSH Term Description Entries
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux
October 1977, La Nouvelle presse medicale,
M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux
March 1977, Revue du rhumatisme et des maladies osteo-articulaires,
M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux
January 1980, Agents and actions. Supplements,
M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux
July 1982, La Clinica terapeutica,
M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux
June 1976, Revue du rhumatisme et des maladies osteo-articulaires,
M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux
January 1981, Acta chirurgiae plasticae,
M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux
April 1979, Annals of the rheumatic diseases,
M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux
October 1978, La Nouvelle presse medicale,
M Alcalay, and D Alcalay, and J F Reboux, and M Devries, and D Bontoux
November 1969, Annals of physical medicine,
Copied contents to your clipboard!